Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Lupus Nephritis (BELONG)
NCT00626197Phase 3Terminated
- Sponsor
- Genentech
- Start
- Feb 2008
- Primary completion
- Oct 2009
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of ocrelizumab in lupus nephritis (LN), sponsored by Genentech. Started Feb 2008; status: terminated.
02
Drugs
ocrelizumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT00626197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00626197.